Accesso libero

Systemic inflammation, TNM staging and survival in patients with lung cancer

Ionela Erhan

Ionela Erhan

”Dr. Carol Davila” Central Military Emergency Universitary Hospital BucharestRomania
Cerca questo autore su
Sciendo|Google Scholar
Erhan, Ionela
, 
Stefan Dumitrache-Rujinski

Stefan Dumitrache-Rujinski

  • Carol Davila University of Medicine and PharmacyBucharest, Romania
  • Marius Nasta Institute of PulmonologyBucharest, Romania
Cerca questo autore su
Sciendo|Google Scholar
Dumitrache-Rujinski, Stefan
, 
Claudia Toma

Claudia Toma

  • Carol Davila University of Medicine and PharmacyBucharest, Romania
  • Marius Nasta Institute of PulmonologyBucharest, Romania
Cerca questo autore su
Sciendo|Google Scholar
Toma, Claudia
 e 
Miron Bogdan

Miron Bogdan

  • Carol Davila University of Medicine and PharmacyBucharest, Romania
  • Marius Nasta Institute of PulmonologyBucharest, Romania
Cerca questo autore su
Sciendo|Google Scholar
Bogdan, Miron
  
31 dic 2020
Systemic inflammation, TNM staging and survival in patients with lung cancer's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Scarica la copertina
Categoria dell'articolo: Original Papers
Pubblicato online: 31 dic 2020
Pagine: 81 - 86
DOI: https://doi.org/10.2478/pneum-2020-0016
Parole chiave
© 2020 Ionela Erhan et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Difference between NLR, PLR and ESR values in resectable versus nonresectable stages.
Difference between NLR, PLR and ESR values in resectable versus nonresectable stages.

Figure 2

Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group A (resectable stages of lung cancer).
Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group A (resectable stages of lung cancer).

Figure 3

Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group B (nonresectable stages of lung cancer).
Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group B (nonresectable stages of lung cancer).

The value of NLR, PLR and ESR in the two subsets of Group A (n=31) and Group B (n=71)

NLRPLRESR (mm/h)
Subset As (survivors, n=11)2,36 (0,87–8.36)138,82 (21,61–416,66)15 (6–110)
Subset Ad (deceased, n=20)2,77 (1,25–12,94)132,57 (41,11–371,17)62 (11–135)
Subset Bs (survivors, n=8)1,40 (1,32–1,73)112,89 (91,14–140,54)31 (9–90)
Subset Bd (deceased, n=63)3,59 (0,70–26,60)183,50 (3,38–651,25)44 (3–120)

Characteristic of the patients with resectable (Group A) and nonresectable (Group B) lung cancer

102 patientsAge (years)History of smoking (No, %)PA (No)Ne (/mm3)Ly (/mm3)PI (/mm3)NLRPLRESR (mm/h)
Group A (resectable stages) 31 (23 men)65 (51–83)23 74,2%40 (3–100)6380 (2600-22.000)2000 (1020-13.600)294.000 (111.000–709.000)2,74 (0,87–12,94)133,95 (21,61–416,66)35 (6–135)
Group B (nonresectable stages) 71 (63 men)67 (37–88)60 84,5%40 (4–90)6450 (1800–27.892)1800 (500–15.700)327.000 (23.000–661.000)3,51 (0,76–25,60)170,37 (3.38–651,25)40 (3–120)
Lingua:
Inglese
Frequenza di pubblicazione:
Volume Open
Argomenti della rivista:
Medicina, Medicina clinica, Medicina clinica, altro, Medicina interna, Pneumologia
Feed RSS della rivista